SecBot SecBot
Biotech Drug Report Generated Nov 7, 2026

A-SUQAR

BIXT·BIOXYTRAN, INC
NEUTRAL
Drug Impact Rating3/10
Trial phase
Not applicable (dietary supplement, not a drug)
Time to market
Already in production and available as a dietary supplement in the U.S. Commercial launch in the UAE and Gulf Cooperation Council markets is pending local product registration, with timing uncertain.
Why 3/10
A-SUQAR is a dietary supplement already in production and available for sale, not a drug requiring FDA approval. The next catalyst is commercial launch in UAE/Gulf markets, but timing depends on local regulatory processes and is not a hard binary date. The product represents a small part of Bioxytran's pipeline behind lead asset ProLectin-M, and the company faces going-concern risks. ImpactScore 3 reflects an approved/commercialized product with no pending regulatory binary.
Actionable Insight NEUTRAL

Watch for news on UAE product registration and initial commercial launch by Khoury Medical, which would be the first real revenue test for A-SUQAR. Also monitor Bioxytran's financing activities and the ProLectin-M registrational trial (planned 408-patient study), as the company's going-concern status makes its ability to fund operations the dominant risk.

Price Chart

Loading chart...

Executive Summary

A-SUQAR is a chewable dietary supplement (not a drug) developed by Bioxytran, Inc. (OTCQB: BIXT), a micro-cap clinical-stage biotechnology company. The product contains a proprietary partially hydrolyzed guar gum formulation designed to slow carbohydrate digestion and blunt post-meal blood sugar spikes. It is already in production and regulated as a dietary supplement in the U.S. On November 4, 2026, Bioxytran announced it secured a Free Sale Certificate for the UAE market, working with distribution partner Khoury Medical. However, Bioxytran is a pre-revenue company with an auditor going-concern warning, a $0.023 stock price on the OTCQB, no analyst coverage, and no tracked institutional holders. A-SUQAR is a small commercial sideline; the company's primary value driver remains its lead antiviral candidate ProLectin-M.

How It Works

A-SUQAR is a chewable tablet taken before meals. It contains a proprietary formulation of partially hydrolyzed guar gum (PHGG), a type of soluble fiber. Rather than entering the bloodstream, it works locally in the digestive tract by slowing the intestinal enzymes that break down carbohydrates into glucose, which helps blunt the rise in blood sugar that normally follows a meal.

Trial Status

A-SUQAR is not a drug and has not undergone clinical trials as a therapeutic. It is marketed as a dietary supplement under U.S. FDA structure/function claim rules, which do not require pre-market approval. The product completed manufacturing in October 2026 and has received a government-issued Free Sale Certificate for export to the UAE and Gulf markets.

The Two-Sided Case

▲ Bull Case3
A-SUQAR received a government-issued Free Sale Certificate on November 4, 2026, legalized for use in the UAE, opening a path to a region where roughly 7.5 million adults have diabetes (UAE, Saudi Arabia, Kuwait).
A commercial distribution agreement with Khoury Medical LTD was signed in February 2026, providing a route-to-market without heavy upfront capital spending by Bioxytran.
The product is already in production and can generate early revenue for a company that reported only $177,795 in trailing twelve-month revenue as of June 2026.
▼ Bear Case4
A-SUQAR is a dietary supplement, not an FDA-approved drug. The FDA does not evaluate or approve supplement structure/function claims before marketing, so there is no regulatory barrier protecting the product from competitors.
Bioxytran is a pre-revenue clinical-stage biotech with an auditor going-concern warning (Fruci & Associates II, PLLC, April 2026 10-K) and negative working capital, raising questions about its ability to fund commercialization.
The stock trades at $0.023 on the OTCQB with minimal volume (20,000 shares on Nov 5), no tracked institutional holders, and no analyst coverage, indicating very limited investor interest.
A-SUQAR is a minor part of Bioxytran's pipeline; the company's lead asset is ProLectin-M (antiviral), and A-SUQAR revenue is unlikely to be transformative for the company's financial position.

Upcoming Catalysts

  • Product registration and commercial launch in UAE and Gulf markets (timing uncertain)
  • Potential expansion into Saudi Arabia, Kuwait and other GCC markets

Source Filing

The SecBot filing or press-release report that triggered this drug report:

BIOXYTRAN, INC 8-K BIXT ·Originating report

Sources · 9

Hover a chip for the title
1 markets.businessinsider.com2 stocktitan.net3 markets.businessinsider.com4 accessnewswire.com5 sec.gov6 gosset.ai7 marketscreener.com8 stocktitan.net9 nasdaq.com